Healthcare Brands international Ltd was founded in 2008 with a mission to become a leading distributor of medical devices. Our aim is to bring innovative, needed and fresh thinking to the consumer healthcare marketplace.

Alongside this, our goal is to deliver the very highest levels of customer satisfaction whilst also creating a profitable business for our partners and investors. Healthcare Brands international Ltd secured the rights to market Asonor® from TannerMedico, Denmark, in 2010.

asonor® received FDA CDER listing in 2006 and has been CE-marked in conformity with EEC Directive 93/42/EEC, indicating that the product meets EU safety, health and environmental requirements.

asonor® is now registered in 50 countries worldwide.

Healthcare Brands international Ltd secured the rights to market Nogasin® and Lactacaps® from Verman, Finland, in 2011.

Nogasin® contains the enzyme alpha-galactosidase, which is a dietary supplement that has been shown to improve the digestion of carbohydrates and reduce the symptoms of flatulence.

Lactose intolerance is the inability to digest lactose (milk sugar) in dairy products. Lactacaps® contains Aspergillus oryzae enzyme, which breaks down lactose into two easier absorbed, simple sugars (galactose and glucose) reducing the symptoms of lactose intolerance.

Nogasin® and Lactacaps® will be launched in 2011 – updates to follow !

For further information on Healthcare Brands international Ltd or any of our products please contact us on : customerservices@hbi-ltd.com

Customer Service: customerservices@hbi-ltd.com

Tel: 0844 800 9549

Press Office: EMIPressOffice@Rdcomms.com